Dr. Cheng-I Wang serves as Head of Antibody Development at Albatroz. He is also a Senior Principal Investigator at Singapore Immunology Network (SIgN), A*STAR, Singapore. Cheng-I is a leading therapeutic antibody expert, who worked in the field of drug discovery for several biotechnology and pharmaceutical companies in the USA. Therapeutic antibodies created by his team at A*STAR in the field of infectious diseases and cancer immunotherapy have been licensed by multinational pharmaceutical companies. He also founded Euchloe Bio (immune checkpoint antibodies), acquired by Tessa Therapeutics in 2017.